| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.9 |